Ayhan, AliOzkan, Nazli TopfedaisiOz, MuratComert, Gunsu KimyonCuylan, Zeliha FıratCoban, GoncaTurkmen, OsmanErdem, BakiSahin, HanifiAkbayir, OzgurDede, MuratTuran, Ahmet TanerCelik, HusnuGungor, TayfunHaberal, AliArvas, MacitMeydanli, Mehmet Mutlu2019-05-022019-05-0220182005-0380https://synapse.koreamed.org/Synapse/Data/PDFData/1114JGO/jgo-29-e48.pdfhttp://hdl.handle.net/11727/3117Objective: The purpose of this study was to investigate the prognostic value of lymph node ratio (LNR) in women with stage IIIC endometrioid endometrial cancer (EC). Methods: A multicenter, retrospective department database review was performed to identify patients with stage IIIC pure endometrioid EC at 6 gynecologic oncology centers in Turkey. A total of 207 women were included. LNR, defined as the percentage of positive lymph nodes (LNs) to total nodes recovered, was stratified into 2 groups: LNR1 (<= 0.15), and LNR2 (> 0.15). Kaplan-Meier method was used to generate survival data. Factors predictive of outcome were analyzed using Cox proportional hazards models. Results: One hundred and one (48.8%) were classified as stage IIIC1 and 106 (51.2%) as stage IIIC2. The median age at diagnosis was 58 (range, 30-82) and the median duration of follow-up was 40 months (range, 1-228 months). There were 167 (80.7%) women with LNR <= 0.15, and 40 (19.3%) women with LNR > 0.15. The 5-year progression-free survival (PFS) rates for LNR <= 0.15 and LNR > 0.15 were 76.1%, and 58.5%, respectively (p= 0.045). An increased LNR was associated with a decrease in 5-year overall survival (OS) from 87.0% for LNR <= 0.15 to 62.3% for LNR > 0.15 (p= 0.005). LNR > 0.15 was found to be an independent prognostic factor for both PFS (hazard ratio [HR]= 2.05; 95% confidence interval [CI]= 1.07-3.93; p= 0.03) and OS (HR= 3.35; 95% CI= 1.57-7.19; p= 0.002). Conclusion: LNR seems to be an independent prognostic factor for decreased PFS and OS in stage IIIC pure endometrioid EC.enginfo:eu-repo/semantics/openAccessSurvival RateEndometrioid CarcinomaEndometrial NeoplasmsLymph Node ExcisionDisease-Free Survivalarticle2940004332858000132-s2.0-85059798666